Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry

Hazar V., Kesik V., Karasuc G. T., Ozturk G., Kupesiz A., Kilic S. C., ...Daha Fazla

LEUKEMIA & LYMPHOMA, cilt.59, sa.1, ss.85-96, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 59 Sayı: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1080/10428194.2017.1330472
  • Dergi Adı: LEUKEMIA & LYMPHOMA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.85-96
  • Anahtar Kelimeler: Relapsed or refractory non-Hodgkin lymphoma, children and adolescents, hematopoietic stem cell transplantation, ACUTE LYMPHOBLASTIC-LEUKEMIA, BFM-GROUP, INTENSIVE CHEMOTHERAPY, FRENCH-SOCIETY, CHILDREN, ADOLESCENTS, CHILDHOOD, RECURRENT, ONCOLOGY, THERAPY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

We examined outcomes of 62 pediatric patients with relapsed or refractory non-Hodgkin lymphoma (rr-NHL) who underwent hematopoietic stem cell transplantation (HSCT). The overall survival (OS) and event-free survival (EFS) rates were 65% and 48%, respectively. Survival rates for patients with chemosensitive disease at the time of HSCT were significantly higher than those of patients with chemosensitive disease (69% vs. 37%, p = .019 for OS; 54% vs. 12%, p <. 001 for EFS; respectively). A chemoresistant disease at transplantation was the only factor that predicted a limited OS (hazard ratio = 10.00) and EFS (hazard ratio = 16.39) rates. Intensive chemotherapy followed by HSCT could be an effective strategy for treating children with rr-NHL and may offer improved survival for a significant group of pediatric patients, particularly those with chemosensitive disease at transplantation.